$3.94
+0.06
(+1.55%)▲
0.73%
Downside
Day's Volatility :1.93%
Upside
1.2%
55.58%
Downside
52 Weeks Volatility :79.12%
Upside
52.98%
Period | Calcimedica Inc | Index (Russel 2000) |
---|---|---|
3 Months | -28.81% | 0.0% |
6 Months | -30.34% | 0.0% |
1 Year | 11.49% | 0.0% |
3 Years | -38.7% | -20.2% |
Market Capitalization | 42.0M |
Book Value | $1.61 |
Earnings Per Share (EPS) | 15.78 |
PE Ratio | 0.25 |
Wall Street Target Price | 16.44 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -43.49% |
Return On Equity TTM | -76.09% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -21.4M |
Diluted Eps TTM | 15.78 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.56 |
EPS Estimate Next Year | -1.56 |
EPS Estimate Current Quarter | -0.67 |
EPS Estimate Next Quarter | -0.57 |
What analysts predicted
Upside of 317.26%
Sell
Neutral
Buy
Calcimedica Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Calcimedica Inc | -16.74% | -30.34% | 11.49% | -38.7% | -38.7% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Calcimedica Inc | 0.25 | 0.25 | NA | -1.56 | -0.76 | -0.43 | NA | 1.61 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Calcimedica Inc | Buy | $42.0M | -38.7% | 0.25 | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Calcimedica Inc
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 50.1%
calcimedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases.
Organization | Calcimedica Inc |
Employees | 13 |
CEO | Dr. A. Rachel Leheny Ph.D. |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$3.94
+1.55%
Keyarch Acquisition Corp
$3.94
+1.55%
Connexa Sports Technologies Inc
$3.94
+1.55%
Us Value Etf
$3.94
+1.55%
First Wave Biopharma Inc
$3.94
+1.55%
Global X Msci Next Emerging
$3.94
+1.55%
Fat Projects Acquisition Corp
$3.94
+1.55%
Capital Link Global Fintech
$3.94
+1.55%
Applied Uv Inc
$3.94
+1.55%